NCT02873325View on ClinicalTrials.gov

Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT

TerminatedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

May 11, 2016

Primary Completion Date

February 23, 2017

Study Completion Date

February 23, 2017

Conditions
Infectious Complications Following HSCT
Interventions
OTHER

antiviral therapies for CMV and/or ADV

salvage antiviral treatments for ADV and/or CMV

Trial Locations (2)

Unknown

Birmigham Children Hospital, Birmingham

Bristol Royal Hospital For Children, Bristol

Sponsors

Lead Sponsor

Cell Medica Ltd
All Listed Sponsors
lead

Cell Medica Ltd

INDUSTRY

NCT02873325 - Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT | Biotech Hunter | Biotech Hunter